Investigation on the IL-18 -607A/C and -137C/G on the susceptibility of ischemic stroke

Jin-he Shi, Li-dan Niu, Xi-yan Chen, Jing-yu Hou, Ping Yang, Guang-peng Li

ABSTRACT

Objective: We conducted a case-control study with 322 cases and 322 controls to assess the role of the two common SNPs in the promoter of IL-18 gene.

Methods: Polymerase chain reaction restriction fragment length of polymorphism (PCR-RFLP) was taken to genotype -607A/C and -137C/G in the promoter of the IL-18 gene.

Results: By comparing cases and control subjects, we found that IS cases were more likely to have higher BMI, higher proportion of hypertension, and have higher proportion of smokers and drinkers. We found that IL-18 -607CC genotype (OR=1.70, 95% CI=1.03-2.81) and C allele (OR=1.26, 95% CI=1.01-1.58) were significantly more frequent in IS patients when compared with AA genotype. We did not find significant association between IL-18 -607A/C gene polymorphism and BMI, hypertension, smoking and drinking on the risk of IS.

Conclusion: Our study suggests that polymorphisms in IL-18 -607A/C can influence the development of IS, and this gene polymorphism is associated with risk of IS in a Chinese population.

KEY WORDS: IL-18, Ischemic stroke, Polymorphism.
as well as lymphotoxin-a.\textsuperscript{4-8} IL-18 is a member of the IL-1 superfamily, and this gene is a pleiotropic pro-inflammatory cytokine and has a role in the inflammatory cascade.\textsuperscript{9} Two previous studies have reported that higher level of IL-18 is associated with increased risk of IS.\textsuperscript{10,11}

It is reported that the IL-18 gene is located on the region of chromosome 11q22.2-q23.3.\textsuperscript{12,13} There were two common gene polymorphisms, -607A/C(rs1946518) and -137C/G(rs187238), in the promoter of IL-18 gene. Previous studies have shown that C allele of IL-18-607A/C and G allele of IL-18-137C/G could affect the IL-18 higher transcription and its protein production.\textsuperscript{14,15} Previous studies have also shown that IL-18 gene polymorphisms are correlated with risk of cardiovascular disease.\textsuperscript{16,17} However, few studies have reported the association between IL-18 polymorphisms and risk of IS.

In order to assess the role of the two common SNPs of the promoter of IL-18 gene in the risk of IS, we conducted a case-control study with 322 cases and 322 controls in a Chinese population.

\textbf{METHODS}

\textbf{Subjects:} Our study included 322 patients who were first onset of IS, and all the patients with IS were selected from the First Affiliated Hospital of Xinxiang Medical University between January 2011 and January 2013. The diagnosis of IS was based on the clinical, cardiac, ultrasound and brain Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) tests. The diagnosis criteria was according to World Health Organization, and that is rapidly development of clinical signs of focal or global disturbance of cerebral function lasting $>$ 24 hours with no apparent cause but vascular origin. Cases who had type 2 diabetes, transient ischemic attacks, intracranial hemorrhage, congestive heart failure, postseizure palsy and brain tumor as well as asthma were excluded from this study.

The controls were frequency-matched with cases by age and sex. 322 control subjects were collected from the health check-up center of the First Affiliated Hospital of Xinxiang Medical University, who came to our hospital for regular health check-up. An informed consent was obtained from all participants before enrolling into our study. The protocol of this study was approved by the First Affiliated Hospital of Xinxiang Medical University.

The age, sex, Body Mass Index (BMI), smoking and drinking habits, hypertension and diabetes were collected by a self-designed questionnaire. The BMI was calculated by weight divided by height squared. Hypertension was assessed according to hypertension guidelines from World Health Organization.

\textbf{Genotyping assays:} A 5mL sample of venous blood was collected from each IS case and control subject after enrolling into our study. The blood samples were kept at -20°C until use, and EDTA 0.5 mg/ml was used to be anticoagulant for blood samples. Genomic DNA was extracted from the whole blood using a TIANamp blood DNA kit (Tiangen Biotech, Beijing, China) according to manufacturer’ instructions.

Polymerase chain reaction restriction fragment length of polymorphism (PCR-RFLP) was taken to genotype -607A/C and -137C/G in the promoter of the IL-18 gene. The PCR primers of IL-18 -607A/C & -137C/G were designed using primer 5.0 software according to the manufacturer’ instructions. Primers for -607A/C were 5'-GTGCAGAAAGTGTAAAAATTATTAC-3' (Forwards) and 5'-GTGCAGAAAGTGTAAAAATTATTAA-3' (Reverse), and primers for -137C/G were 5'-CCCCAACTTTTACGGAAGAAAAC-3' and 5'-CCCCAACTTTTACGGGAAGAAAAC-3'.

Amplification was conducted using the following processes: beginning with an initial denaturation for 5 minutes at 95°C, followed by 35 step cycles of denaturation at 95°C for 30s, annealing at 62°C for 30s, and extension at 72°C for 30s, and a final extension was taken at 72°C for 10 minutes. PCR products of IL-18 gene were assessed by 1.0% agarose gel electrophoresis and ultraviolet light. In order to perform quality control, we randomly selected 5% of IS cases and controls to repeat genotype, and we found the reproducibility was 100%.

\textbf{Statistical Analysis:} Continuous variables were shown as mean ± SD, and categorical variables were shown as frequencies and percentage (%). The continuous and categorical variables between cases and controls were compared by the $\chi^2$-test or student t test. A $\chi^2$-test was taken to assess the Hardy–Weinberg equilibrium of genotype distributions of control group. After adjusting potential risk factors of IS, a multivariate logistic regression analysis was performed to compare the genotype distributions of -607A/C and -137C/G in the promoter of the IL-18 gene between case and control groups. The results were expressed by an odds ratio (OR) and 95% confidence interval (95% CI). The homozygous genotypes of IL-18 -607A/C and -137C/G genotypes were used to be reference group. Two-sided P-values were taken to use in our
study and a P-value $<0.05$ was defined as statistically significant. All statistical analyses were performed using STATA 9.0 software.

RESULTS

The demographic and lifestyle characteristics of IS patients and control subjects were shown in Table-I. There was no significant difference in terms of sex and age between cases and controls. By comparing characteristics between IS cases and control subjects, we found that IS cases were more likely to have higher BMI, higher frequency of hypertension, and have higher frequency of smokers and drinkers than control subjects.

The genotype and allele frequencies of IL-18 -607A/C and -137C/G are shown in Table-II. The genotype and allele frequencies of the IL-18 -607A/C and -137C/G in controls did not deviate from Hardy-Weinberg equilibrium in the case and control groups. There was significant difference in the allele frequencies in terms of -607A/C between cases and controls ($P<0.05$) (Table-II).

Table-I: Distributions of the demographic & lifestyle characteristics.

| Characteristics     | Cases     | %      | Controls | %      | $t$ or $\chi^2$ | $p$ value |
|---------------------|-----------|--------|----------|--------|-----------------|-----------|
| Age, years          |           |        |          |        |                 |           |
| Mean +SD, years     | 62.4±9.3  | 61.8±10.6 | 170      | 52.80  |                 |           |
| <60                 | 149       | 46.27  | 170      | 52.80  |                 |           |
| ≥60                 | 173       | 53.73  | 152      | 47.20  | 2.74            | 0.10      |
| Sex                 |           |        |          |        |                 |           |
| Male                | 204       | 63.35  | 204      | 63.35  |                 |           |
| Female              | 118       | 36.65  | 118      | 36.65  |                 | 1.00      |
| BMI(kg/m²)          |           |        |          |        |                 |           |
| <25                 | 207       | 64.29  | 233      | 72.36  |                 |           |
| ≥25                 | 115       | 35.71  | 89       | 27.64  | 4.85            | 0.03      |
| Diabetes            |           |        |          |        |                 |           |
| No                  | 73        | 22.67  | 59       | 18.32  |                 |           |
| Yes                 | 249       | 77.33  | 263      | 81.68  | 1.87            | 0.17      |
| Hypertension        |           |        |          |        |                 |           |
| No                  | 181       | 56.21  | 263      | 81.68  |                 |           |
| Yes                 | 141       | 43.79  | 82       | 18.32  | 62.99           | $<0.001$  |
| Smoking             |           |        |          |        |                 |           |
| Non-smoker          | 92        | 28.57  | 56       | 17.39  |                 |           |
| Current or ex-smoker| 230       | 71.43  | 266      | 82.61  | 1.9             | $<0.001$  |
| Drinking            |           |        |          |        |                 |           |
| No                  | 105       | 32.61  | 133      | 41.30  |                 |           |
| Yes                 | 217       | 67.39  | 189      | 58.70  | 5.23            | 0.02      |

Table-II: Associated of IL-18 genotypes with risk of IS.

| IL-18 polymorphism | Cases | %   | Controls | %   | $p$ value  | OR(95% CI) |
|--------------------|-------|-----|----------|-----|------------|------------|
| -607A/C genotype   |       |     |          |     |            |            |
| AA                 | 54    | 16.77 | 71       | 22.05 | -          | 1.0(Ref.)  |
| AC                 | 180   | 55.9 | 183      | 56.83 | 0.22       | 1.29(0.84-1.99) |
| CC                 | 88    | 27.33 | 68       | 21.12 | 0.03       | 1.70(1.03-2.81) |
| Allele             |       |     |          |     |            |            |
| A                  | 288   | 44.72 | 325      | 50.47 | -          | 1.0(Ref.)  |
| C                  | 356   | 55.28 | 319      | 49.53 | 0.04       | 1.26(1.01-1.58) |
| -137C/G genotype   |       |     |          |     |            |            |
| CC                 | 11    | 3.42 | 18       | 5.59  | -          | 1.0(Ref.)  |
| CG                 | 81    | 25.16 | 84       | 26.09 | 0.27       | 1.58(0.66-3.94) |
| GG                 | 230   | 71.43 | 220      | 68.32 | 0.17       | 1.71(0.75-4.10) |
| Allele             |       |     |          |     |            |            |
| C                  | 103   | 15.99 | 120      | 18.63 | -          | 1.0(Ref.)  |
| G                  | 541   | 84.01 | 524      | 81.37 | 0.21       | 1.20(0.89-1.62) |

1. Adjusted for sex, age, BMI, diabetes, hypertension, smoking and drinking.
IL-18 -607CC genotype (OR=1.70, 95% CI=1.03-2.81) and C allele (OR=1.26, 95% CI=1.01-1.58) were significantly more frequent in IS patients when compared with AA genotype (Table-II). However, we did not find significant association of IL-18 -137C/G gene polymorphism with risk of IS.

We further investigated the association between IL-18 -607A/C gene polymorphism and BMI, hypertension, smoking and drinking on the risk of IS (Table-III). Stratified analysis showed that an increased risk of IS was associated with those carrying IL-18 -607AC+CC, even in those with higher BMI, hypertension, smoking and drinking habits. However, no statistical significant difference was found between them, and no significant interaction between IL-18 -607A/C gene polymorphism and BMI, hypertension, smoking and drinking on the risk of IS.

Table-III: Association between IL-18 -607A/C gene polymorphism and demographic characteristics on the risk of IS.

| Characteristics | -607AA | -607AC+CC | OR(95%CI) | p value |
|-----------------|--------|-----------|-----------|---------|
| BMI(kg/m²)      |        |           |           |         |
| <25             | 36     | 171       | 1.33(0.81-2.21) | 0.24    |
| ≥25             | 18     | 97        | 1.56(0.72-3.38) | 0.21    |
| Hypertension    |        |           |           |         |
| No              | 31     | 150       | 1.77(0.90-3.45) | 0.07    |
| Yes             | 23     | 118       | 1.32(0.74-2.39) | 0.32    |
| Smoking         |        |           |           |         |
| Non-smoker      | 13     | 79        | 1.49(0.55-3.92) | 0.38    |
| Current or ex-smoker | 41 | 189       | 1.34(0.84-2.15) | 0.19    |
| Drinking       |        |           |           |         |
| No              | 19     | 86        | 1.21(0.60-2.45) | 0.56    |
| Yes             | 35     | 182       | 1.53(0.90-2.60) | 0.09    |

1. Adjusted for sex and age.

DISCUSSION

The etiologies of IS are highly complicated and not well understood, and both environmental and genetic factors play a role in the development of IS, such as smoking, drinking, hypertension, diabetes and some genetic polymorphisms. Previous studies indicated that several certain polymorphisms in inflammatory genes can influence the risk of IS, such as interleukin-6 (IL-6), transforming growth factor (TGF-B1), interleukin-1 receptor antagonist (IL-1Ra), IL-1a and IL-1B and tumor necrosis factors.4-8 The current study showed that IL-18 -607A/C polymorphisms can influence the risk of IS.

Genetic polymorphisms of cytokines can influence the expression or function of these cytokines, and polymorphisms in the genes can regulate the inflammatory mechanisms that play an important role in the pathology and development of IS. Previous study has shown that genetic polymorphisms of IL-18 -607A/C and -137C/G in the promoter IL-18 gene may affect the immune response, and can have a role in the risk of several kinds of diseases, such as tuberculosis, cancers, coronary artery disease and stroke.16-21

IL-18 -607A/C and -137C/G are located at the promoter of IL-18 gene, and previous studies have showed that the -607A allele and -137C allele are correlated with higher expression of IL-18.22,23 IL-18 has a role in causing spread and instability of atherosclerotic plaque, and previous studies have shown that IL-18 gene variations are associated with vascular changes in the carotid artery and associated with risk of coronary artery disease.16,24,25 Altering expression of IL-18 can cause the proliferation of human aortic smooth muscle cell, and thus induce the progress of atherosclerosis.26,27 Moreover, IL-18 is also involved in neuroinflammation in hypoxic-ischemic brain injuries.28 Only two previous clinical studies have shown that IL-18 gene polymorphisms are associated with development of IS.20,21 Zhang et al. investigated the association between IL-18 -607A/C and -137C/G and risk of ischemic stroke, and reported that -607C allele was associated with an increased risk of IS, and -137G allele was associated with increased risk of larger artery atherosclerosis.20 Lu et al. reported that IL-18-607C/A promoter polymorphism can influence the risk of IS, and C allele was correlated with an increased risk.21 The results of our study were in line with previous studies, our study reported that
607C allele was associated with increased risk of IS. Several strengths can be considered in our study. First, the diagnosis of IS was used a rigorous method. The diagnosis of IS was based on the clinical, cardiac, ultrasound and brain Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) tests. Second, a relative larger sample size was taken in our study, which enhances the statistical power to find the difference between groups. Some limitations also should be considered in our study. First, our study is a case-control design, and thus a selection bias could not be avoided for the case and control groups. Second, this study might be applied only to our populations due to ethnicity differences. Third, other inflammatory gene polymorphisms may have a role in the development of IS, and may have interaction with IL-18 gene polymorphisms. Therefore, further large sample studies with more ethnics are needed.

In conclusion, our study suggests that polymorphisms in IL-18 -607A/C can influence the development of IS, and this gene polymorphism is associated with risk of IS in a Chinese population. Our study supports the hypothesis that IL-18 gene polymorphism is associated with risk of IS, which suggests that further therapeutic studies should be conducted to reduce the activity of IL-18 to prevent the risk of IS.

REFERENCES

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S. Heart disease & stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(4):e213-215. doi: 10.1161/CIRCULATIONAHA.109.192667.

2. Dichiagis M. Genetics of ischemic stroke. Lancet Neurol. 2007;6(2):149-161. doi: 10.1016/S1474-4422(07)70029-5.

3. Lindberg PJ, Grau AJ. Inflammation & infections as risk factors for ischemic stroke. Stroke. 2005;36(10):2518-2532. doi: 10.1161/01.STR.0000089015.51603.CC.

4. Banerjee I, Gupta V, Ahmed T, Faizaan M, Agarwal P, Ganesh S. Inflammatory system gene polymorphism & the risk of stroke: a case-control study in an Indian population. Brain Res Bull. 2008;75(1):158-165. doi: 10.1016/j.brainresbull.2007.08.007.

5. Bis JC, Heckbert SR, Smith NL, Reiner AP, Rice K, Lumley T, et al. Variation in inflammation-related genes & risk of incident nondal myocardial infarction or ischemic stroke. Atherosclerosis. 2008;198(1):166-173. doi: 10.1016/j.atherosclerosis.2007.09.031.

6. Kim Y, Lee C. The gene encoding transforming growth factor beta 1 confers risk of ischemic stroke & vascular dementia. Stroke. 2006;37(11):2843-2845. doi: 10.1161/01.STR.0000244782.76917.17.

7. Lee BC, Ahn SY, Doo HK, Yim SV, Lee HJ, Jin SY, et al. Susceptibility for ischemic stroke in Korean population is associated with polymorphisms of the interleukin-1 receptor antagonist and tumor necrosis factor-alpha genes, but not the interleukin-1beta gene. Neurosci Lett. 2004;357(1):33-36. doi: 10.1016/j.neulet.2003.12.041.

8. Li N, He X, Xu J, Liu F, Dong S, Zhang H. Association of PDE4D & IL-1 gene polymorphism with ischemic stroke in a Han Chinese population. Brain Res Bull. 2010;81(1):38-42. doi: 10.1016/j.brainresbull.2009.09.009.

9. Okamura H, Tsutou H, Kashiwamura S, Yoshimoto T, Nakanihni K. Interleukin-18: a novel cytokine that augments both innate & acquired immunity. Adv Immunol. 1996;70:281-312.

10. Yuen CM, Chiu CA, Chang LT, Liu CW, Lu CH, Youssef AA, et al. Level & value of interleukin-18 after acute ischemic stroke. Circ J. 2007;71(11):1691-1696. doi: 10.1253/circj.71.1691.

11. Zaremja J, Lowy J. Interleukin-18 in acute ischaemic stroke patients. Neurol Sci. 2003;24(3):117-124.

12. Koch W, Wollfertetter H, Schatte A, Schömg A, Kastrati A. Interleukin 18 gene variation and risk of acute myocardial infarction. Cyto. 2011;56(3):766-791. doi: 10.1016/j.cytos.2011.09.006.

13. Kim HJ, Cho SO, Kim SY, Kim SH, Chung WS, Chung SH, et al. Association of interleukin-18 gene polymorphism with body mass index in women. Reprod Biol Endocrinol. 2012;10:31. doi: 10.1186/1477-7827-10-31.

14. Giedraitis V, He B, Huang WX, Hillert J. Cloning & mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001;112(1-2):146-152.

15. Bai J, Zhang Y, Lin M, Zeng X, Wang Z, Shen J. Interleukin-18 gene polymorphisms & haplotypes in patients with oral lichen planus: a study in an ethnic Chinese cohort. Tissue Antigens. 2007;70(5):390-397. doi: 10.1111/j.1399-0039.2007.00922.x.

16. Opstad TB, Pettersen AA, Arnesen H, Seljellot I. The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients. PLoS One. 2013;8(9):e74498. doi: 10.1371/journal.pone.0074498.

17. Hernesniemi JA, Anttila K, Nieminen T, Kahonen M, Mononen N, Nikus K, et al. IL-18 gene polymorphism, cardiovascular mortality & coronary artery disease. Eur J Clin Investig. 2010;40(11):994-1001. doi: 10.1111/j.1365-2656.2010.03256.x.

18. Tsai HT, Hsin CH, Hsieh YH, Tang CH, Yang SF, Lin CW, et al. Impact of interleukin-18 polymorphisms -607A/C & -137C/G on oral cancer occurrence & clinical progression. PLoS One. 2013;8(12):e83572. doi: 10.1371/journal.pone.0083572.

19. Yu XL, Zhao F, Zhang J, Pan XM. IL-18 genetic polymorphisms may contribute to the pathogenesis of tuberculosis among Asians: a meta-analysis of case-control studies. Mol Biol Rep. 2014 Jun 27. [Epub ahead of print]

20. Zhang N, Yu JT, Yu NN, Lu RC, Ma T, Wang ND, et al. Interleukin-18 promoter polymorphisms & risk of ischemic stroke. Brain Res Bull. 2010;81(6):590-594. doi: 10.1016/j.brainresbull.2010.01.008.

21. Lu JX, Lu ZQ, Zhang SL, Zhi J, Chen ZP, Wang WX. Correlation between interleukin-18 promoter -607C/A & susceptibility to ischemic stroke. Braz J Med Biol Res. 2013;46(6):502-506. doi: 10.1590/1414-431X20132850.

22. Khripko OP, Sennikova NS, Lopatinokova JA, Khripko JL, Filipenko ML, Khrapov EA, et al. Association of single nucleotide polymorphisms in the IL-18 gene with production of IL-18 protein by mononuclear cells from healthy donors. Mediators Inflamm. 2008;2008:309721. doi: 10.1155/2008/309721.

23. Giedraitis V, He B, Huang WX, Hillert J. Cloning & mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001;112(1-2):146-152.

24. Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med. 2009;6(3):192-199. doi: 10.1038/nccardio1453.

25. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein Er/-/- mice through release of interferon-gamma. Circ Res. 2002;90(2):E34-E38. doi: 10.1161/01.HTJ.0000073682.98776.93.

26. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874.

27. Liu W, Tang Q, Jiang H, Ding X, Liu Y, Zhu R, et al. Promoter polymorphism of interleukin-18 in angiographically proven coronary artery disease. Angiology. 2009;60(1):180-185. doi: 10.1111/j.1394-9236.2008.00303.x.

28. Felderhoff-Mueser U, Schmutz OI, Stahrholzer A, Bühler C, Stahel PF. IL-18: a key player in inflammation & neurodegeneration? Trends Neurosci. 2005;28(9):487-493. doi: 10.1016/j.tins.2005.06.008.

Author's Contributions:

JHS: Conceived, designed and did statistical analysis & editing of manuscript.

LDN, XYC, JYH, PY & GPL: Did data collection and manuscript writing.